147 related articles for article (PubMed ID: 18216394)
1. Development of binding assays for the SH2 domain of Grb7 and Grb2 using fluorescence polarization.
Luzy JP; Chen H; Gril B; Liu WQ; Vidal M; Perdereau D; Burnol AF; Garbay C
J Biomol Screen; 2008 Feb; 13(2):112-9. PubMed ID: 18216394
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.
Gunzburg MJ; Ambaye ND; Del Borgo MP; Pero SC; Krag DN; Wilce MC; Wilce JA
J Mol Recognit; 2012 Jan; 25(1):57-67. PubMed ID: 22213451
[TBL] [Abstract][Full Text] [Related]
4. Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain.
Liu WQ; Vidal M; Gresh N; Roques BP; Garbay C
J Med Chem; 1999 Sep; 42(18):3737-41. PubMed ID: 10479306
[TBL] [Abstract][Full Text] [Related]
5. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
Wei CQ; Gao Y; Lee K; Guo R; Li B; Zhang M; Yang D; Burke TR
J Med Chem; 2003 Jan; 46(2):244-54. PubMed ID: 12519063
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs.
Liu WQ; Vidal M; Olszowy C; Million E; Lenoir C; Dhôtel H; Garbay C
J Med Chem; 2004 Feb; 47(5):1223-33. PubMed ID: 14971902
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7.
Pero SC; Oligino L; Daly RJ; Soden AL; Liu C; Roller PP; Li P; Krag DN
J Biol Chem; 2002 Apr; 277(14):11918-26. PubMed ID: 11809769
[TBL] [Abstract][Full Text] [Related]
10. Uptake of a cell permeable G7-18NATE contruct into cells and binding with the Grb-7-SH2 domain.
Ambaye ND; Lim RC; Clayton DJ; Gunzburg MJ; Price JT; Pero SC; Krag DN; Wilce MC; Aguilar MI; Perlmutter P; Wilce JA
Biopolymers; 2011; 96(2):181-8. PubMed ID: 20564009
[TBL] [Abstract][Full Text] [Related]
11. Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor.
Thömmes K; Lennartsson J; Carlberg M; Rönnstrand L
Biochem J; 1999 Jul; 341 ( Pt 1)(Pt 1):211-6. PubMed ID: 10377264
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.
Furet P; Gay B; Caravatti G; García-Echeverría C; Rahuel J; Schoepfer J; Fretz H
J Med Chem; 1998 Aug; 41(18):3442-9. PubMed ID: 9719597
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7.
Janes PW; Lackmann M; Church WB; Sanderson GM; Sutherland RL; Daly RJ
J Biol Chem; 1997 Mar; 272(13):8490-7. PubMed ID: 9079677
[TBL] [Abstract][Full Text] [Related]
14. Progress towards the development of SH2 domain inhibitors.
Kraskouskaya D; Duodu E; Arpin CC; Gunning PT
Chem Soc Rev; 2013 Apr; 42(8):3337-70. PubMed ID: 23396540
[TBL] [Abstract][Full Text] [Related]
15. Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands.
Shi ZD; Wei CQ; Lee K; Liu H; Zhang M; Araki T; Roberts LR; Worthy KM; Fisher RJ; Neel BG; Kelley JA; Yang D; Burke TR
J Med Chem; 2004 Apr; 47(8):2166-9. PubMed ID: 15056012
[TBL] [Abstract][Full Text] [Related]
16. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.
Lung FD; Tsai JY
Biopolymers; 2003; 71(2):132-40. PubMed ID: 12767115
[TBL] [Abstract][Full Text] [Related]
17. Cyclic Peptides Incorporating Phosphotyrosine Mimetics as Potent and Specific Inhibitors of the Grb7 Breast Cancer Target.
Watson GM; Gunzburg MJ; Ambaye ND; Lucas WA; Traore DA; Kulkarni K; Cergol KM; Payne RJ; Panjikar S; Pero SC; Perlmutter P; Wilce MC; Wilce JA
J Med Chem; 2015 Oct; 58(19):7707-18. PubMed ID: 26359549
[TBL] [Abstract][Full Text] [Related]
18. Utilization of 3'-carboxy-containing tyrosine derivatives as a new class of phosphotyrosyl mimetics in the preparation of novel non-phosphorylated cyclic peptide inhibitors of the Grb2-SH2 domain.
Song YL; Tan J; Luo XM; Long YQ
Org Biomol Chem; 2006 Feb; 4(4):659-66. PubMed ID: 16467940
[TBL] [Abstract][Full Text] [Related]
19. Solution structure of the human Grb14-SH2 domain and comparison with the structures of the human Grb7-SH2/erbB2 peptide complex and human Grb10-SH2 domain.
Scharf PJ; Witney J; Daly R; Lyons BA
Protein Sci; 2004 Sep; 13(9):2541-6. PubMed ID: 15322292
[TBL] [Abstract][Full Text] [Related]
20. Development of l-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity.
Song YL; Roller PP; Long YQ
Bioorg Med Chem Lett; 2004 Jun; 14(12):3205-8. PubMed ID: 15149676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
